ArticleHealth science reports2026
Donor-Related Factors Affecting Haploidentical HSCT Outcomes in Acute Leukemia: A Single-Center Retrospective Cohort Study of a Modified Combination of Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) provides curative therapy for patients lacking HLA-matched donors, yet optimal donor characteristics remain uncertain. This study assessed the effect of donor relationship, age, sex, and ABO compatibility on outcomes of haplo-HSCT for acute leukemia under a uniform ATG/post-transplant cyclophosphamide (PTCy)-based protocol. Methods: In this retrospective single-center cohort, 159 adults with acute myeloid or lymphoblastic leukemia received peripheral blood haplo-HSCT following myeloablative busulfan/cyclophosphamide plus ATG and PTCy (2015-2022). Overall survival (OS), disease-free survival (DFS), GVHD-free/relapse-free survival (GRFS), and relapse incidence were analyzed using Kaplan-Meier and Fine-Gray methods; predictors were evaluated by multivariable Cox regression. Results: Of 159 patients, 96/159 (60.4%) had AML and 63/159 (39.6%) had ALL. Donors were siblings in 90/159 (56.6%), parents in 48/159 (30.2%), and offspring in 21/159 (13.2%). Median recipient age was 27 years (range, 15-59), and median donor age was 31 years (range, 2-65). At 36 months, unadjusted outcomes varied across donor groups. In AML, OS was 52.7% (95% CI, 38.8-64.9) with sibling donors, 52.3% (95% CI, 29.4-71.0) with parent donors, and 32.1% (95% CI, 9.5-57.9) with offspring donors. In ALL, offspring donors were associated with numerically lower survival and higher relapse. In multivariable analysis, ALL (HR, 1.99; 95% CI, 1.25-3.17; Conclusions: In this single-center cohort of adults undergoing haploidentical HSCT with a uniform ATG/PTCy-based platform, donor relationship was associated with descriptive differences in unadjusted outcomes, but it was not an independent predictor in multivariable models. The inferior outcomes observed with offspring donors appeared to be influenced in part by older recipient age. Trial Registration: Not applicable (retrospective study).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.